Breadcrumb

[A18-20] Emicizumab (haemophilia A) - Benefit assessment according to §35a Social Code Book V

Overview

Overview

Commission: Commission awarded on 2018-03-27 by the Federal Joint Committee (G-BA)
Status:Commission completed
Department/Division:Drug Assessment
Current document:PDF Extract of dossier assessment  [PDF, 132 kB]Further documents
Note:

After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.

Contact address:to the contact form
Linked projects: [A19-26] Emicizumab (haemophilia A) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed

[A18-49] Emicizumab (haemophilia A) - Addendum to Commission A18-20
Status: Commission completed


Report documents

Report documents

PublishedDocumentSizeType 
2018-07-02 Extract of dossier assessment 132 kBPDFdownload file
2018-07-02 Dossier assessment (German version) 742 kBPDFdownload file

After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.


At a glance

Accompanying information

Extract of dossier assessment

  File-Icon  Emicizumab (haemophilia A) - Benefit assessment according to §35a Social Code Book V [PDF, 132 kB]

Federal Joint Committee (G-BA)

2018-09-20 A G-BA decision was published.

G-BA documents on this decision

Press releases

2018-07-02 Haemophilia A and sialorrhoea: comparator therapies not implemented, added benefit not proven



Save result list

To save your search result, please copy the link below and paste it into a new tab/window.

close